Locally produced autoantibodies in cancer
- PMID: 35364029
- DOI: 10.1016/j.cell.2022.03.006
Locally produced autoantibodies in cancer
Abstract
The function and antigen-specificities of tumor-infiltrating B cells are mostly unknown. In a new study by Mazor et al., matrix metalloproteinase 14 (MMP14), a self-antigen that is overexpressed by ovarian cancers, is shown to drive B cell activation and autoantibody production in tertiary lymphoid structures (Mazor et al., 2022).
Copyright © 2022 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests Sana Biotechnology has licensed intellectual property of D.B. and Washington University in St. Louis. Gilead Sciences has licensed intellectual property of D.B. and Stanford University. D.B. is a co-founder of Clade Therapeutics. D.B. is on an advisory panel for GlaxoSmithKline. S.M.C. has no conflicts of interests.
Comment on
-
Tumor-reactive antibodies evolve from non-binding and autoreactive precursors.Cell. 2022 Mar 31;185(7):1208-1222.e21. doi: 10.1016/j.cell.2022.02.012. Epub 2022 Mar 18. Cell. 2022. PMID: 35305314
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical